**Military Hospital**

**Pharmaceutical services**

**Intensive care units**

**Local protocol for Hyperglycaemia Control in Intensive Care Units of Military Hospital, Sudan, 2020**

**Developed by:**

**Ghada Omer Hamad Abd El-Raheem - American board certified Critical Care Pharmacist**

**Contacts: +24992623636- +249922572830, E-mail: ghadaomer90@gmail.com**

**Approved by**

Kamal Osman, Training supervisor in critical care- Intensivist

Mudawi Abdallah, Medical Director of intensive care units – Clinical Pharmacist

Azmi Elshaikh, General Manager of intensive care units- Intensivist

Sami Aqeed, Intensivist

Selma Elamin, Head of department of pharmaceutical services- Clinical Pharmacist

**Endorsed for application:**

Pending till publication of national guidelines by Ministry of Health

# **TABLE OF CONTENTS**

[**TABLE OF CONTENTS** 2](#_Toc39973329)

[**1.** **INTRODUCTION** 3](#_Toc39973330)

[**2.** **GLYCEMIC CONTROL IN HYPERGLYCEMIC ADULT CRITICAL CARE PATIENTS (NON- DIABETIC)- Nottingham University Hospitals (NUH)** [5] 4](#_Toc39973331)

[**3.** **GLYCEMIC CONTROL IN DIABETIC ADULT CRITICAL CARE PATIENTS (TYPE 1, TYPE 2) AND PATIENTS WITH TOTAL PENCREATIC RESECTION- Nottingham University Hospitals (NUH)** [5] 5](#_Toc39973332)

[**4.** **SWITHCHING FROM INTRAVENOUS INSULIN TO ORAL AGENTS OR SUBCUTANEOUS INSULIN** 6](#_Toc39973333)

[**5.** **GLYCEMIC CONTROL IN ACUTE CORONARY SYNDROMES- ACS (STEMI, NSTEMI, UNSTABLE ANGINA)- Nottingham University Hospitals (NUH)** [12] 8](#_Toc39973334)

[**6.** **DIABETIC KETO- ACIDOSIS (DKA) MANAGEMENT** 10](#_Toc39973335)

[**7.** **HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS) MANAGEMENT** 12](#_Toc39973336)

[**8.** **SPECIAL PATIENTS POPULATION** 13](#_Toc39973337)

[**8.1.** **Patients with renal impairment:** 13](#_Toc39973338)

[**8.2.** **Patients on renal replacement therapy:** 13](#_Toc39973339)

[**8.3.** **Patients on steroid therapy:** 13](#_Toc39973340)

[**8.4.** **Patients on vasopressors:** 13](#_Toc39973341)

[**8.5.** **Patients on total parenteral nutrition (TPN):** 13](#_Toc39973342)

[**8.6.** **Patients undergoing cardiac surgery (CABG):** 14](#_Toc39973343)

[**9.** **RECOMMENDATIONS FOR NURSES** 15](#_Toc39973344)

[**10.** **RECOMMENDATIONS FOR DOCTORS** 16](#_Toc39973345)

[**11.** **FREQUENTLY ASKED QUESTIONS (FAQ)** 17](#_Toc39973346)

[**REFERENCES** 18](#_Toc39973347)

**Hyperglycemia control policy for critically ill patients in intensive care units**

1. **INTRODUCTION**

* In critically ill or hemodynamically unstable patients, treatment using intravenous infusions is favorable as it enables frequent rate adjustments according to patients BG level [1]
* For all adult critical care patients in medical Intensive Care Units (ICUs), the target random blood glucose (RBG) is 140- 180 mg/dl [2].
* For patients with ischemic stroke, intra-parenchymal hemorrhage, subarachnoid hemorrhage (SAH) and traumatic brain injury (TBI), the target RBG is 150 mg/dl and absolutely less than 180 mg/dl and avoid RBG less than 100 mg/dl [3, 4].
* Nottingham University Hospitals (NUH) guidelines [5] use the NICE-SUGAR target.
* Systematic review conducted by American College of Physician (ACP) concluded that no reduction in mortality using intensive insulin therapy for patients with myocardial infarction, acute brain injury or stroke [6].
* Before starting insulin infusion, you must always check RBG twice using different techniques (finger-prick and venous samples). If the RBG level is higher than 180 mg/dl for 2 readings 1 hour apart then insulin infusions might be prescribed [5].
* Insulin infusions are prepared using 50 units of regular insulin (Actrapid) insulin (drawn up by insulin syringe) plus 49.5 ml of normal saline to make a total volume of 50 mls [5].
* Insulin infusions must be accompanied by dextrose containing fluids or feeding (enteral, parenteral), if fluids and feeding stopped insulin infusions must be stopped [5].
* Check RBG when there are new symptoms like sweating, tachycardia, hypotension or loss of consciousness [5].
* Stable patients who are fully conscious can restart their previous anti-diabetics (subcutaneous insulin or even oral anti-diabetics) 1 hour before stopping insulin infusion, and random blood glucose (RBG) should be measured every 2 hours for the next 6 hours then less frequently [5].
* Do not take the blood samples from the same line that has been receiving glucose containing fluid [5].
* When the RBG readings are within the target range for 3 consecutive readings (Yale protocol), you can then check it every 6 hours [7].

1. **GLYCEMIC CONTROL IN HYPERGLYCEMIC ADULT CRITICAL CARE PATIENTS (NON- DIABETIC)- Nottingham University Hospitals (NUH)** [5]

|  |  |  |
| --- | --- | --- |
| **Random blood glucose level ( RBG)** | **Insulin infusion rate** | **Next RBG** |
| 180- 216 mg/dl | 1 unit/hour | After 1 hour |
| 217- 270 mg/ dl | 2 units/hour | After 1 hour |
| 271- 324 mg/dl | 3 units/hour | After 1 hour |
| > 324 mg/dl | 4 units/hour and inform medicals | After 1 hour |

**Notes:**

* Higher insulin doses should be given if the RBG readings are always higher than 252 mg/dl.

**Hypoglycemia (Yale protocol)** [7]**:**

|  |  |  |
| --- | --- | --- |
| **Random blood glucose level ( RBG)** | **Insulin infusion rate** | **Next RBG reading** |
| <50 mg/dl | Discontinue insulin infusion and give 50 ml Dextrose 50% (D50%) IV | Every 15 minutes till RBG>90 mg/dl, then wait 30 minutes and restart insulin infusion at half the rate. |
| 50- 74 mg/dl | Discontinue insulin infusion and give 25 ml of D 50% IV | Every 15 minutes till RBG>90 mg/dl, then wait 30 minutes and restart insulin infusion at half the rate. |
| 75- 99 mg/dl | Discontinue insulin infusion | Every 15 minutes till RBG>90 mg/dl, then wait 30 minutes and restart insulin infusion at 75% of the rate. |

# **GLYCEMIC CONTROL IN DIABETIC ADULT CRITICAL CARE PATIENTS (TYPE 1, TYPE 2) AND PATIENTS WITH TOTAL PENCREATIC RESECTION- Nottingham University Hospitals (NUH)** [5]

|  |  |  |
| --- | --- | --- |
| **Random blood glucose level ( RBG)** | **Insulin infusion rate** | **Next RBG reading** |
| 72- 124.2 mg/dl | 1 unit/hour | After 1 hour |
| 126- 178.2 mg/dl | 2 units/hour | After 1 hour |
| 180- 268.2 mg/ dl | 3 units/hour | After 1 hour |
| 270- 358.2 mg/dl | 4 units/hour | After 1 hour |
| > 360 mg/dl | 5 units/ hour and inform medicals | After 1 hour |

**Notes:**

* Higher insulin doses should be given if the RBG readings are always higher than 252 mg/dl and for patients who were taking high insulin doses.

**Hypoglycemia (Yale protocol)** [7]**:**

|  |  |  |
| --- | --- | --- |
| **Random blood glucose level ( RBG)** | **Insulin infusion rate** | **Next RBG** |
| <50 mg/dl | Discontinue insulin infusion and give 50 ml Dextrose 50% (D50%) IV | Every 15 minutes till RBG>90 mg/dl, then wait 30 minutes and restart insulin infusion at half the rate. |
| 50- 74 mg/dl | Discontinue insulin infusion and give 25 ml of D 50% IV | Every 15 minutes till RBG>90 mg/dl, then wait 30 minutes and restart insulin infusion at half the rate. |
| 75- 99 mg/dl | Discontinue insulin infusion | Every 15 minutes till RBG>90 mg/dl, then wait 30 minutes and restart insulin infusion at 75% of the rate. |

# **SWITHCHING FROM INTRAVENOUS INSULIN TO ORAL AGENTS OR SUBCUTANEOUS INSULIN**

Stable adult diabetic patients can restart their anti-diabetic medications ( oral tablets or S.C. insulin) 1 hour before stopping the insulin infusion. The patient must be fed.

Check RBG every 2 hours for at least 6 hours after the first tablet and every hour for 2 hours, then 2 hourly for 24 hours after S.C. insulin [5].

Stable non- insulin requiring patients who were on 2units/hour regimen can be discharges without insulin, RBG should be checked within 4 hours after stopping insulin [5].

American college of critical care medicine guidelines recommend that stable critical care patients should be transitioned to subcutaneous basal- bolus insulin regimen [4]. Switching from intravenous I.V. to subcutaneous S.C. insulin should be done properly to avoid loss of glycemic control by starting the basal S.C. insulin 1 hour before stopping the insulin infusion.

**Basal- Bolus insulin regimen ( subcutaneous regimen):**

* 50%- 60% of the total daily I.V. insulin is the recommended dose of the basal insulin ( insulin glargine [Lantus] ), in other words, half the I.V. insulin dose in the past 24 hours is the dose of Lantus insulin to be started 1 hour before stopping the insulin infusion, ideally following a meal [8,9]. This method provides good glycemic control with low risk of hypoglycemia.
* RBG should be measured every 1 hour for 2 hours then every 2 hours for 24 hours.
* For stable patients in which basal-bolus is to be started without knowing the total daily insulin. We use weight based estimate of TDI as follows [10]:

|  |  |
| --- | --- |
| **Type 1 diabetes** | dose |
| Initial dose | 0.3-0.5 unit/Kg/day |
| Honeymoon phase | 0.2-0.5 unit/Kg/day |
| **Type 2 diabetes** |  |
| With insulin resistance | 0.7-1.5 unit/Kg/day |

* Basal insulin: insulin glargine (Lantus). Given once daily, it controls fasting blood glucose. Lantus dose is half the total insulin daily dose.
* Bolus insulin: regular insulin (Actrapid). Given three times daily before meals, it controls post- prandial blood glucose. Ideally, the estimation of bolus insulin doses is done using the “500 rule”, dividing 500 by the total daily insulin (TDI) will estimate the carbohydrate amount in gm that 1 unit of bolus insulin will cover. Otherwise fixed dose method can be applied using half the total daily insulin dose divided to 3 doses and each dose is given before meals [11].

**Correctional insulin needs:**

If fixed dose did not provide optimal glycemic control and the RBG is still high, then additional doses of regular insulin are needed. The estimated dose to be given is calculated using the “1500 rule” in which 1500/TDI= number of mg/dl of RBG that are lowered per 1 unit of regular insulin.

Example: if the TDI is 50 units/ day, 1500/50= 30, suggesting that I unit of regular insulin will reduce RBG level by 30 mg/dl.

Advantage of this method is that it mimics natural insulin secretion patterns, hence called insulin therapy. Besides it is more patient specific than traditional sliding- scale regimen. Also using Lantus insulin (peak-less long acting insulin) is less hypoglycemic than using NPH insulin twice daily and more flexible [11].

1. **GLYCEMIC CONTROL IN ACUTE CORONARY SYNDROMES- ACS (STEMI, NSTEMI, UNSTABLE ANGINA)- Nottingham University Hospitals (NUH)** [12]

All ACS patients should have their RBG checked on admission. Target RBG is between 72 mg/dl to 198 mg/dl.

Generally, poor quality studies exist for glycemic control in ACS. The aim is to achieve target RBG either by using intravenous or subcutaneous insulin administered within 4 hours of hospital admission.

**Notes:**

* Hyperglycemia after ACS suggests high risk of type 2 diabetes.
* Fasting blood glucose should be assessed 4 days after ACS and HbA1c should be checked before discharge.
* If patient is stable and can take orally (eats food and drinks) then resume home antidiabetics.

**Basal- Bolus insulin regimen ( subcutaneous regimen):**

* 50%- 60% of the total daily I.V. insulin is the recommended dose of the basal insulin ( insulin glargine{ Lantus}), in other words, half the I.V. insulin dose in the past 24 hours is the dose of Lantus insulin to be started 1 hour before stopping the insulin infusion ideally following a meal [8,9]. This method provides good glycemic control with low risk of hypoglycemia.
* RBG should be measured every 1 hour for 2 hours then every 2 hours for 24 hours.
* For stable patients in which basal-bolus is to be started without knowing the total daily insulin. We use weight based estimate of TDI as follows [10]:

|  |  |
| --- | --- |
| **Type 1 diabetes** | **dose** |
| Initial dose | 0.3-0.5 unit/Kg/day |
| Honeymoon phase | 0.2-0.5 unit/Kg/day |
| **Type 2 diabetes** | **dose** |
| With insulin resistance | 0.7-1.5 unit/Kg/day |

* Basal insulin: insulin glargine (Lantus). Given once daily, it controls fasting blood glucose. Lantus dose is half the total insulin daily dose.
* Bolus insulin: regular insulin (Actrapid). Given three times daily before meals, it controls post- prandial blood glucose. Ideally, the estimation of bolus insulin doses is done using the “500 rule”, dividing 500 by the total daily insulin (TDI) will estimate the carbohydrate amount in gm that 1 unit of bolus insulin will cover. Otherwise fixed dose method can be applied using half the total daily insulin dose divided to 3 doses and each dose is given before meals.

**Correctional insulin needs:**

If fixed dose did not provide optimal glycemic control and the RBG is still high, then additional doses of regular insulin are needed. The estimated dose to be given is calculated using the “1500 rule” in which 1500/TDI= number of mg/dl of RBG that are lowered per 1 unit of regular insulin.

Example: if the TDI is 50 units/ day, 1500/50= 30, suggesting that I unit of regular insulin will reduce RBG level by 30 mg/dl.

Advantage of this method is that it mimics natural insulin secretion patterns, hence called insulin therapy. Besides it is more patient specific than traditional sliding- scale regimen. Also using Lantus insulin (peak-less long acting insulin) is less hypoglycemic than using NPH insulin twice daily and more flexible [11].

1. **DIABETIC KETO- ACIDOSIS (DKA) MANAGEMENT**

**American College of Clinical Pharmacy (ACCP)** [3]**, Applied Therapeutics** [10]**, injectable drugs guide** [13]

**Fluids administration:**

* In the absence of cardiac problems, administer normal saline (NS) with a rate of 1- 1.5 liter during the first hour, then at a rate of 250- 500 ml/hr to target hemodynamic parameters and urine output.
* When random blood glucose (RBG) reaches 200 mg/dl switch fluids to Dextrose ½saline, and if unavailable continue NS infusion and add dextrose 10% infusion at a rate of 125 ml/hour.

**Insulin:**

* Bolus dose: 0.1 units/Kg intravenously I.V.
* Maintenance dose: 0.1/kg/hour I.V.
* If RBG does not decrease by 50 mg/dl in the first hour, double the rate of insulin infusion.
* Measure RBG hourly and titrate insulin infusion to target decrease of RBG by 50- 75 mg/dl/hour.
* Reduce the rate to (0.02-0.05 u/Kg/h) or 0.1 u/Kg/h (if started with double the rate) when RBG reaches 200 mg/dl and switch fluids from NS to dextrose in ½ saline to maintain RBG between 150 – 200 mg/dl **[do not stop the insulin infusion].**
* Once the patient is out of the DKA (, give subcutaneous (S.C.) insulin dose (0.5- 0.8 u/Kg/d) **1 hour before stopping the insulin infusion.**
* Relief of DKA includes the following three criteria: RBG < 200 mg/dl , serum bicarbonate≥ 15mg/dl and PH> 7.3 [3].

**Potassium (K):**

* If K<3.3 mEq/L, give KCl with a rate of 20- 40 mEq/hour before starting insulin infusion.
* If K> 5.2 mEq/L do not give KCl and check serum potassium every 2 hours, if it falls below 4 mE/L start Kcl infusion.
* If K> 3.3 and < 5.3 mEq/L, give 20- 30 mEq in each liter. In other words give half ampoule of KCl with each bottle of fluid to maintain potassium level between 4- 5 mEq/L.

**Bicarbonate: (consultant decision only)**

* If PH falls below 6.9 (or bicarbonate <10 mEq/L), give Sodium bicarbonate (NaHCO3), 50 ml of NaHCO3 8.4% (1 ampoule) is given via central line over 1 hour [10]. Or by dissolving 100 ml of NaHCO3 8.4% in 400 ml water for injection and 20 mEq KCl by rate 200ml/hour. Once PH is above 7 stop the Bicarbonate infusion [3].

**Phosphorus:**

* Give phosphorous if serum concentration is < 1mg/dl.

**Monitoring:**

* Check RBG hourly and electrolytes every 2 hours to avoid hypokalemia or hypo/hypernatremia.
* Measure ketones (blood or urine) every 1 hour.
* Measure bicarbonate level and PH (arterial blood gas ABG) every 2 hours [10].

1. **HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS) MANAGEMENT**

**American College of Clinical Pharmacy (ACCP)** [3]**, NUH** [5]

**Fluids administration:**

* Fluids only (NS) at the beginning might correct HHS.
* In the absence of cardiac problems, administer normal saline (NS) with a rate of 1- 1.5 Liter during the first hour, then at a rate of 250- 500 ml/hr.
* When random blood glucose (RBG) reaches 300 mg/dl switch to Dextrose ½saline, and if unavailable continue NS infusion and add dextrose 10% infusion at a rate of 125 ml/hour.

**Insulin:**

* Measure RBG hourly and start insulin infusion to target decrease of RBG by 50- 75 mg/dl/hour (< 90 mg/dl/hour). Start at a rate of 0.05 u/Kg/hour
* Reduce the rate to 0.02 U/Kg/h when RBG reaches 300 mg/dl and switch fluids from NS to dextrose in ½ saline, **[do not stop the insulin infusion]** and maintain RBG between 200- 300 mg/dl till mental status changes resolve.
* Once the patient is stable, give subcutaneous (S.C.) insulin dose (0.5- 0.8 u/Kg/d) **1 hour before stopping the insulin infusion.**

**Potassium (K):**

* If K<3.3 mEq/L, give KCl with a rate of 20- 40 mEq/hour before starting insulin infusion.
* If K> 5.2 mEq/L do not give KCl and check serum potassium every 2 hours, if it falls below 4 mE/L start Kcl infusion.
* If K> 3.3 and < 5.3 mEq/L, give 20- 30 mEq in each liter. In other words give half ampoule of KCl with each bottle of fluid to maintain potassium level between 4- 5 mEq/L.

**Additional managements:**

* Treat underlying causes (infection, cardiac events…)
* Administer thrombo-prophylaxis (enoxaparin 40 mg S.C. once daily) if no contraindications.
* Provide foot care and daily checks.
* After weeks to months, the patients can be transferred to oral anti-diabetics.
* Give phosphorous if serum concentration is < 1mg/dl.

**Monitoring:** Check RBG hourly and electrolytes every 2 hours to avoid hypokalemia or hypo/hypernatremia.

1. **SPECIAL PATIENTS POPULATION**
   1. **Patients with renal impairment:**

Patients with renal impairment are more sensitive to insulin because insulin is removed renally, moderate renal failure patients (GFR > 22.5 ml/min remove only 39% of endogenous and exogenous insulin, while in severe renal impairment (GFR < 6 ml/min), only 9% of insulin is removed. So when administering insulin we should pay attention and start with low doses (0.4 of the normal dose up to 0.1 of the normal doses for fourth stage renal impairment) [10].

* 1. **Patients on renal replacement therapy:**

Reduce the dose by 25- 50% and titrate according to response, can be given any time during dialysis

* 1. **Patients on steroid therapy:**

Higher rates of insulin infusions might be needed, because steroids increase insulin resistance [1], increased insulin requirements are about 20% [5].

* 1. **Patients on vasopressors:**

Higher rates of insulin infusions might be needed, because Catecholamines increase insulin resistance [1].

* 1. **Patients on total parenteral nutrition (TPN):**
     1. ***Diabetic patients on TPN:***

Give 1 unit of regular insulin for each 10 gm of dextrose used in preparation of TPN mixture. This dose of insulin is either added to the TPN mixture or given in a separate infusion.

If the BG level still high (above 140 mg/dl), then increase the rate of infusion by 0.5 units for each 10 gm of dextrose [1].

* + 1. ***Non- diabetic hyperglycemic patients on TPN:***

Give 1 unit of regular insulin for each 20 gm of dextrose used in preparation of TPN mixture. This dose of insulin is either added to the TPN mixture or given in a separate infusion [1].

If the BG is still high (above 140 mg/dl) increase the rate to be 1 unit per 15 gm of dextrose.

* 1. **Patients undergoing cardiac surgery (CABG):**

Tight glycemic control for 3 post- operative days has been shown to have benefits more than risks [14, 15], but ACP stated that no mortality benefit of tight insulin therapy during perioperative period [6].

For diabetic patients undergoing cardiac surgery, GLUCO- CABG trail showed no difference in morbidity or mortality between tight (110-140 mg/dl) and conventional glucose levels (140- 180 mg/dl) [16].

American college of critical care medicine recommends BG target less than 150 mg/dl for cardiac surgery patients [4].

In conclusion NICE-SUGAR target is optimum for diabetic patients undergoing coronary artery bypass graft surgery [16].

1. **RECOMMENDATIONS FOR NURSES**

* Before starting insulin infusion always check RBG twice using different techniques (finger-prick and venous samples). If RBG level is higher than 180 mg/dl for 2 readings 1 hour apart then insulin infusions may be prescribed [5].
* Insulin infusions are made using 50 units Actrapid insulin (drawn up by insulin syringe) plus 49.5 ml of normal saline to make a total volume of 50 mls [5].
* Flush 20 mls of the made fluid through the I.V. set first before administration because insulin adheres to the infusion bag and set [10].
* Change the insulin infusion every 24 hours and the infusion set and cannula every 72 hours [13].
* Insulin infusions must be accompanied by dextrose containing fluids or feeding (enteral, parenteral), if fluids and feeding stopped insulin infusions must be stopped [5].
* Do not take the blood samples from the line that contains glucose containing fluid.
* When the RBG readings are within the target for 3 consecutive readings (Yale protocol), you can then check it every 6 hours.
* Check RBG when there is new sweating, tachycardia, hypotension or loss of consciousness.

1. **RECOMMENDATIONS FOR DOCTORS**

* Note that patients on insulin infusions are at risk of developing hypokalemia, so supplementary potassium might be needed for most patients except hyperkalemic patients and patients with eGFR< 15ml/min/1.73 m2 [9].

|  |  |  |  |
| --- | --- | --- | --- |
| Criteria | Infusion fluid | Additives | Rate (ml/hr) |
| K< 4.9mmol/L  (eGFR>15ml/min/1.73 m2 | Dextrose 5%  1000 ml | KCl 40 mmol | 100ml/hr |
| K< 4.9mmol/L  ( on fluid restriction) | Dextrose 10%  500 ml | KCl 20 mmol | 50ml/hr |
| K>5 mmol/L | Dextrose 10%  500 ml | NONE | 50ml/hr |
| eGFR<15ml/min/1.73 m2 or dialysis | Dextrose 10%  500 ml | NONE | 50ml/hr |

* Always prescribe long acting insulin [Lantus] along with the insulin infusion. If the admitted patient is taking Lantus, keep administering it at usual dose and time, and also for all hyperglycemic patients for better control of BG during insulin infusion Lantus is better to be given [9].
* Do not forget that insulin infusions should be stopped 1 hour after starting the subcutaneous insulin [8, 9].
* Do not forget administering dextrose containing fluids (or substrates) while administering insulin infusions [8,9].

1. **FREQUENTLY ASKED QUESTIONS (FAQ)**
2. **Do we give K supplementation in fluids extra to the maintenance fluids the patient is currently taking?**

No, give K in the maintenance fluids, give 40 mmol (2 ampules of KCl) in 1000 ml of maintenance fluids (40 mmol/day).

1. **Can we give K in dextrose containing fluids?**

Yes.

1. **If the patients RBG is high, can we give insulin boluses along with the infusion?**

Yes, but there is higher risk of hypoglycemia. We can give boluses of I.V regular insulin with consultation of the doctor and monitoring RBG every 30 minutes. (Portland Protocol) [7]. The following table can be used for administering insulin boluses, but this algorithm provides tighter control (80-120 mg/dl).

|  |  |
| --- | --- |
| **Blood Glucose (mg/dl)** | **Bolus I.V regular insulin** |
| 181-240 | 6 units |
| 241-300 | 8 |
| 301-360 | 12 |
| >360 | 16 |

1. **Can we give S.C. insulin glargine along with the insulin infusion?**

Yes, and it is recommended as it provides better control without the risk of hypoglycemia, if the patient already taking it continue with the same dose, and if it is to be started calculate the dose estimation using weight [10].

1. **What if all control measures did not get the RBG to the Target levels?**

We can use (WU) algorithms 3 or 4 after **consultation of endocrinologist**

|  |  |  |
| --- | --- | --- |
| **Blood Glucose (mg/dl)** | **Algorithm-3 (Units/hour)** | **Algorithm-4 (Units/hour)** |
| 180-209 | 5 | 9 |
| 210-239 | 6 | 12 |
| 240-269 | 8 | 16 |
| 270-299 | 10 | 20 |
| 300-329 | 12 | 24 |
| 330-359 | 14 | 28 |
| >360 | 16 |  |

# **REFERENCES**

1. Gosmanov AR, Umpierrez GE. Management of hyperglycaemia during enteral and parenteral nutrition therapy. Curr Diab Rep.2013; 13(1): 155-162.
2. Finfer S, Chittock D, et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study. Intensive Care Med. 2015;41(6):1037-1047. doi:10.1007/s00134-015-3757-6
3. Dickerson R. Fluids, electrolytes, acid-base disorders and nutrition support. In: Bass S, Benken ST, et al., eds. Critical Care Pharmacy Preparatory Review and Recertification Course, 2019 ed. Lenexa, KS: American College of Clinical Pharmacy, 2019: P 83- 137.
4. Bass SN, Bauer SR. Hepatic failure/GI/endocrine emergencies. In: Bass S, Benken ST, et al., eds. Critical Care Pharmacy Preparatory Review and Recertification Course, 2019 ed. Lenexa, KS: American College of Clinical Pharmacy, 2019: P 569- 626.
5. Alrifai Z, Beed M, Javaid A, Jamieson E. Management and monitoring of insulin infusions and glycemic control in adult critical care patients. Nottingham University Hospitals NHS; 3. 2020. P 19.
6. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011;154(4):260-267. Doi:10.7326/0003-4819-154-4-201102150-00007
7. Steil, G. M., Deiss, D., Shih, J., Buckingham, B., Weinzimer, S., & Agus, M. S. D. (2009). Intensive Care Unit Insulin Delivery Algorithms: Why So Many? How to Choose? Journal of Diabetes Science and Technology, 3(1), 125–140. <https://doi.org/10.1177/193229680900300114>.
8. Doolin MK, Walroth TA, Harris SA, Whitten JA, Fritschle-Hilliard AC. Transition From Intravenous to Subcutaneous Insulin in Critically Ill Adults. J Diabetes Sci Technol. 2016;10(4):932-938. Published 2016 Jun 28. Doi:10.1177/1932296816629985
9. Clayton J. Guideline for Variable Rate Insulin Infusion (VRIII) prescription and supplementary fluid prescription. Nottingham University Hospitals NHS. 2018; 2: P 12.
10. Alldredge, B. K., Corelli, R. L., Ernst, M. E., Guglielmo, B. J., Jacobson, P. A., Kradjan, W. A., & Williams, B. R. (2013). Koda-Kimble and Young's applied therapeutics: The clinical use of drugs. Wolters Kluwer Health Adis (ESP).
11. Irons BK. Endocrine and metabolic disorders. ACCP updates in therapeutics: The pharmacotherapy preparatory review and recertification course. 2019; volume (1): p 655-708.
12. Erhayiem B. Guidance based on NICE clinical guideline 130 ‘Management of hyperglycaemia in acute coronary syndromes’ - Issued: October 2011 - [www.nice.org.uk/cg130](http://www.nice.org.uk/cg130).
13. Gray A, Write J, Googey V, Bruce L. Injectable drugs guide. Pharmaceutical Press. London. 2011. ISBN 978 0 85369 787 9.
14. Klonoff DC. Intensive insulin therapy in critically ill-hospitalized patients: making it safe and effective. J Diabetes Sci Technol; 2011: 755-767. Doi:10.1177/193229681100500330
15. Furnary AP. Clinical benefits of tight glycaemic control: focus on the perioperative setting. Best Pract Res Clin Anaesthesiol. 2009; 23 (4): 411-420.
16. Umpierrez G, Cardona S, Pasquel F, et al. randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CONTROL Trial. 2015; 38: 1665-1672.